As a Free StocksGuide user, you can view scores for all 6,951 stocks worldwide.
8 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:
8 Analysts have issued a EyeGate Pharmaceuticals, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 0.02 0.02 |
100%
100%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -11 -11 |
528%
528%
|
EBIT (Operating Income) EBIT | -11 -11 |
537%
537%
|
Net Profit | -12 -12 |
629%
629%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes EGP-437 and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.
Head office | United States |
CEO | Brian Strem |
Employees | 12 |
Founded | 1998 |
Website | kiorapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.